Kerx Inc. Short kill - 500 Beiträge pro Seite

[paula5]

es scheint los zugehn

[paula5]

hier mal das short vol. Short % of Float (as of May 31, 2012)3: 16.30%
Shares Short (prior month)3: 10.04M

[paula5]

wenn die 2,00$ fällt fliegt sie den jungs richtig um die ohren

[MACD]

Ich halte es für zu kurz gedacht bei diesen Werten immer nur auf das short interest zu schauen. Man weiß ja nicht aus welchen Gründen die Aktien short gehalten werden.
Vielleicht sind es z. B. Market Maker die diese short-bestande in Kombination mit Optionen halten und verschiedenste Risikoprofile erzeugen, die müssen dann erstmal gar nicht covern...
Wer würde auch eine Aktie bei 1,60 shorten bzw. bei anderen noch viel tiefer mit diesem begrenzten Profit aber unbegrenztem Risiko nach oben? Das kann man nur machen wenn man als Insider genau weiß das aus dem Laden nichts anderes mehr wird als ein Insolvenzfall.

Ebenso wird das alles nichts bringen wenn das Unternehmen sich nicht positiv (FDA-Zulassungen, Verkaufserlöse etc.)entwickelt in der Zukunft.

[paula5]

http://finance.yahoo.com/news/keryx-biopharmaceuticals-annou…

[paula5]

[paula5]

..Merger and Acquisition Activity and Speculation Growing as Large Pharmaceuticals Look to Replace Revenues From Lost Patents
Five Star Equities Provides Stock Research on Dendreon and Keryx Biopharmaceuticals

Press Release: Five Star Equities – 2 hours 11 minutes ago....
Share0EmailPrint.....Companies:...Dendreon Corp.Keryx Biopharmaceuticals Inc. . ..RELATED QUOTES.
.Symbol Price Change
DNDN 7.37 -0.08

......NEW YORK, NY--(Marketwire -07/03/12)- Despite the recent economic slowdown, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 30 percent and 32 percent, respectively. As the world continues to face evolving health challenges the discoveries of new therapeutics and vaccines are critical. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Dendreon Corporation (DNDN) and Keryx Biopharmaceuticals (KERX).

Access to the full company reports can be found at:

www.FiveStarEquities.com/DNDN
www.FiveStarEquities.com/KERX

Expiring patents have been a major dilemma for pharmaceutical companies. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. The Obama administration is currently analyzing a proposal in which the exclusivity period for biologics would be cut down by 5 years. Mergers & Acquisitions activity is expected to pick up in 2012 as companies scramble to look to make up for loss revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development.

"Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.

Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Dendreon is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. Net product revenue for the first quarter was $82.0 million compared to $27.0 million for the quarter ended March 31, 2011.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer